Kenneth Wu

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis
    K K Wu
    Department of Internal Medicine, University of Texas Houston Health Science Center, 77030, USA
    Ann Med 32:73-7. 2000
  2. ncbi Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators
    K K Wu
    Vascular Biology Research Center and Division of Hematology, Department of Internal Medicine, Institute of Molecular Medicine and Medical School, University of Texas Health Science Center at Houston, TX 77030, USA
    Prostaglandins Leukot Essent Fatty Acids 72:89-93. 2005
  3. ncbi Transcriptional Control of COX-2 via C/EBPbeta
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5 016, Houston, TX 77030, USA
    Arterioscler Thromb Vasc Biol 25:679-85. 2005
  4. ncbi Control of COX-2 and iNOS gene expressions by aspirin and salicylate
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, Department of Internal Medicine, University of Texas Health Science Center, 6431 Fannin, Houston, TX 77030, USA
    Thromb Res 110:273-6. 2003
  5. ncbi Transcription-based COX-2 inhibition: a therapeutic strategy
    Kenneth K Wu
    Vascular Biology Research Center and Division of Hematology, Department of Medicine, The University of Texas Health Science Center at Houston, Texas 77030, USA
    Thromb Haemost 96:417-22. 2006
  6. ncbi Soluble thrombomodulin and coronary heart disease
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and The University of Texas Houston Medical School, Houston, TX 77030, USA
    Curr Opin Lipidol 14:373-5. 2003
  7. ncbi Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease
    Kenneth K Wu
    Vascular Biology Research Center and Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, Tex, USA
    Circulation 107:1729-32. 2003
  8. ncbi Aspirin and other cyclooxygenase inhibitors: new therapeutic insights
    Kenneth K Wu
    Vascular Biology Research Center and Division of Hematology, The University of Texas Houston Health Science Center, Houston, TX 77030 1503, USA
    Semin Vasc Med 3:107-12. 2003
  9. ncbi Novel mechanisms of aspirin pharmacologic actions: a model for studying herbal natural products
    Kenneth K Wu
    Vascular Biology Research Center, The Brown Foundation Institute of Molecular Medicine and Division of Hematology, Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
    Thromb Res 117:61-4; discussion 65-7. 2005
  10. ncbi Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts
    Kenneth K Wu
    Vascular Biology Research Center at Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX, USA
    Prostaglandins Other Lipid Mediat 83:175-81. 2007

Collaborators

Detail Information

Publications61

  1. ncbi Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis
    K K Wu
    Department of Internal Medicine, University of Texas Houston Health Science Center, 77030, USA
    Ann Med 32:73-7. 2000
    ..The plasma TM level may reflect the level of endothelial TM expression. TM expression levels are influenced by multiple gene polymorphisms. Several of the polymorphisms are probably associated with coronary heart disease...
  2. ncbi Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators
    K K Wu
    Vascular Biology Research Center and Division of Hematology, Department of Internal Medicine, Institute of Molecular Medicine and Medical School, University of Texas Health Science Center at Houston, TX 77030, USA
    Prostaglandins Leukot Essent Fatty Acids 72:89-93. 2005
    ....
  3. ncbi Transcriptional Control of COX-2 via C/EBPbeta
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5 016, Houston, TX 77030, USA
    Arterioscler Thromb Vasc Biol 25:679-85. 2005
    ..The recent progress sheds light on the pathophysiological mechanisms of COX-2 and new transcription-based strategy for controlling COX-2 overexpression and COX-2-mediated cardiovascular diseases...
  4. ncbi Control of COX-2 and iNOS gene expressions by aspirin and salicylate
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, Department of Internal Medicine, University of Texas Health Science Center, 6431 Fannin, Houston, TX 77030, USA
    Thromb Res 110:273-6. 2003
  5. ncbi Transcription-based COX-2 inhibition: a therapeutic strategy
    Kenneth K Wu
    Vascular Biology Research Center and Division of Hematology, Department of Medicine, The University of Texas Health Science Center at Houston, Texas 77030, USA
    Thromb Haemost 96:417-22. 2006
    ..RSK phosphorylates C/EBPbeta and stimulates its binding to enhancer elements. We propose that RSK1/2 is a potential target for screening drugs with novel anti-inflammatory and anti-neoplastic therapeutic potentials...
  6. ncbi Soluble thrombomodulin and coronary heart disease
    Kenneth K Wu
    Vascular Biology Research Center, Institute of Molecular Medicine and The University of Texas Houston Medical School, Houston, TX 77030, USA
    Curr Opin Lipidol 14:373-5. 2003
    ..The purpose of this review is to provide recent information regarding the relationship of soluble thrombomodulin with coronary heart disease...
  7. ncbi Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease
    Kenneth K Wu
    Vascular Biology Research Center and Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, Tex, USA
    Circulation 107:1729-32. 2003
    ..A high sICAM level increases the risk of CHD, whereas a high level of sTM has a lower risk of CHD. It was unclear whether there was an interaction between sTM and sICAM...
  8. ncbi Aspirin and other cyclooxygenase inhibitors: new therapeutic insights
    Kenneth K Wu
    Vascular Biology Research Center and Division of Hematology, The University of Texas Houston Health Science Center, Houston, TX 77030 1503, USA
    Semin Vasc Med 3:107-12. 2003
    ..These recent studies provide new insight into the pharmacological actions of aspirin and salicylate preparations and implicate C/EBPbeta as a potential target for therapy of inflammation and tissue injury...
  9. ncbi Novel mechanisms of aspirin pharmacologic actions: a model for studying herbal natural products
    Kenneth K Wu
    Vascular Biology Research Center, The Brown Foundation Institute of Molecular Medicine and Division of Hematology, Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA
    Thromb Res 117:61-4; discussion 65-7. 2005
  10. ncbi Differential cyclooxygenase-2 transcriptional control in proliferating versus quiescent fibroblasts
    Kenneth K Wu
    Vascular Biology Research Center at Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX, USA
    Prostaglandins Other Lipid Mediat 83:175-81. 2007
    ....
  11. ncbi Molecular aspects of thrombosis and antithrombotic drugs
    Kenneth K Wu
    Biology Division of Hematology and Vascular Research Center, University of Texas Health Science Center, Houston, TX 77030, USA
    Crit Rev Clin Lab Sci 42:249-77. 2005
    ..Currently available antiplatelet agents target glycoprotein IIbIIIa (abciximab, tirofiban, eptifibatide), cyclooxygenase-1 (aspirin) or adenosine diphosphate receptor, P2Y12 (clopidogrel)...
  12. ncbi Cellular and molecular biology of prostacyclin synthase
    Kenneth K Wu
    Vascular Biology Research Center, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Biochem Biophys Res Commun 338:45-52. 2005
    ..PGIS coupling with COX-2 has been shown to play an important role in vascular protection, embryo development and implantation, and cancer growth...
  13. ncbi Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis
    Jun Yang Liou
    Division of Hematology and Vascular Biology Research Center, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5 016, Houston, Texas 77030, USA
    Stem Cells 25:1096-103. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  14. ncbi Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance
    Jun Yang Liou
    Vascular Biology Research Center and Division of Hematology, Institute of, Molecular Medicine and Medical School, University of Texas Health Science Center at Houston, Houston, TX 77030 1503, USA
    Exp Cell Res 306:75-84. 2005
    ..These results suggest that mitochondrial COX-2 in cancer cells confer resistance to apoptosis by reducing the proapoptotic arachidonic acid...
  15. ncbi Salicylate suppresses macrophage nitric-oxide synthase-2 and cyclo-oxygenase-2 expression by inhibiting CCAAT/enhancer-binding protein-beta binding via a common signaling pathway
    Katarzyna Cieslik
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Houston Health Science Center, 6431 Fannin, Houston, TX 77030, USA
    J Biol Chem 277:49304-10. 2002
    ..Salicylate at pharmacological concentrations is capable of suppressing the early phase of NOS-2 and COX-2 expression by blocking C/EBPbeta binding...
  16. ncbi Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators
    Wu Guo Deng
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center, Houston, TX 77030, USA
    Blood 103:2135-42. 2004
    ..We conclude that p300 is the predominant coactivator that is essential for COX-2 transcriptional activation by proinflammatory mediators...
  17. ncbi Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon
    Jun Yang Liou
    University of Texas Health Science Center, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 67:3185-91. 2007
    ..These results suggest that 14-3-3epsilon is a target for the prevention and therapy of colorectal cancer...
  18. ncbi Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation
    Wu Guo Deng
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, Department of Internal Medicine, University of Texas Health Science Center, Houston, Texas 77030, USA
    J Biol Chem 278:4770-7. 2003
    ..Co-transfection of E1A with p300 abrogated p50 acetylation and p50 binding. These findings suggest that up-regulation of p300 binding and its acetylation of NF-kappaB occupies a central position in COX-2 promoter activation...
  19. ncbi Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts
    Wu Guo Deng
    Vascular Biology Research Center, Institute of Molecular Medicine, and Division of Hematology, University of Texas Houston Medical School, Houston, Texas, USA
    FASEB J 16:1286-8. 2002
    ..These findings provide evidence for the control of COX-2 transcription by an endogenous cellular factor...
  20. ncbi Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins
    Ying Zhu
    Vascular Biology Research Center, Institute of Molecular Medicine, University of Texas Houston Medical School, 6431 Fannin, Houston, TX 77030, USA
    J Biol Chem 277:6923-8. 2002
    ..These findings provide new insight into the regulation of cyclooxygenase-2 promoter by an interplay between two opposite beta isoforms and p300 co-activator...
  21. ncbi Inhibition of p90 ribosomal S6 kinase-mediated CCAAT/enhancer-binding protein beta activation and cyclooxygenase-2 expression by salicylate
    Katarzyna A Cieslik
    Vascular Biology Research Center and Division of Hematology, Brown Foundation Institute of Molecular Medicine and Medical School, The University of Texas Health Science Center and Texas Heart Institute, Houston, Texas 77030 1503, USA
    J Biol Chem 280:18411-7. 2005
    ..We conclude that salicylate inhibits C/EBPbeta-mediated COX-2 transcriptional activation by blocking RSK activity and Ras signaling pathway...
  22. ncbi Oviduct prostacyclin functions as a paracrine factor to augment the development of embryos
    Jaou Chen Huang
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center Houston, Houston, TX 77030, USA
    Hum Reprod 19:2907-12. 2004
    ..However, the eicosanoid profile of mouse oviducts remains unknown...
  23. ncbi Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching
    Jaou Chen Huang
    Department of Obstetrics and Gynecology, University of Texas Health Science Center Houston, Houston, TX 77030, USA
    Hum Reprod 19:2900-6. 2004
    ..The role of prostaglandins (PGs) in embryo hatching remains controversial. In addition, there is no direct evidence that mouse embryos synthesize PGs...
  24. ncbi Essential role of C-Rel in nitric-oxide synthase-2 transcriptional activation: time-dependent control by salicylate
    Katarzyna A Cieslik
    Vascular Biology Research Center at the Brown Foundation Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    Mol Pharmacol 70:2004-14. 2006
    ..We propose that salicylate inhibits C/EBPbeta binding at 4 h and C-Rel binding at 8 and 24 h by targeting related kinases...
  25. ncbi Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation
    Wu Guo Deng
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, Department of Internal Medicine, University of Texas Health Science Center, Houston, TX 77030, USA
    J Immunol 171:6581-8. 2003
    ..We conclude that p300 is essential for iNOS transcription. Our results suggest that p300 HAT acetylates the p50 subunit of NF-kappaB, thereby increasing NF-kappaB binding and NF-kappaB mediated transactivation...
  26. pmc Assessment of coronary heart disease risk by combined analysis of coagulation factors
    Nena Aleksic
    Department of Internal Medicine at Medical School, Vascular Biology Research Center at Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX 77030, USA
    Atherosclerosis 198:294-300. 2008
    ..Prospective studies have reported a positive association of coagulation factors with risk of coronary heart disease (CHD). It is unclear whether these coagulation factors interact...
  27. ncbi Prostacyclin receptor signaling and early embryo development in the mouse
    Jaou Chen Huang
    Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030 USA
    Hum Reprod 22:2851-6. 2007
    ..Prostacyclin (PGI(2)) plays an important role in mouse embryo development and implantation. However, it is unclear whether its action is mediated via the I prostaglandin receptor (IP)...
  28. ncbi Prostacyclin inhibits endothelial cell XIAP ubiquitination and degradation
    Jun Yang Liou
    University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    J Cell Physiol 212:840-8. 2007
    ..Preservation of XIAP proteins represents a key mechanism by which PGI(2) protects endothelial cells from oxidant-induced apoptosis...
  29. ncbi Regulation of endothelial nitric oxide synthase activity and gene expression
    Kenneth K Wu
    Vascular Biology Research Center Institute of Molecular Medicine and Division of Hematology, University of Texas Houston Health Science Center, Houston, Texas, USA
    Ann N Y Acad Sci 962:122-30. 2002
    ..These findings provide new insight into the protective role of eNOS and the therapeutic potential of eNOS gene therapy...
  30. ncbi Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI
    Jaou Chen Huang
    Department of Obstetrics and Gynecology, University of Texas Medical School at Houston, Institute of Molecular Medicine and Division of Hematology, Texas 77030, USA
    J Clin Endocrinol Metab 87:4361-8. 2002
    ..Thus, the fallopian tube expresses both COX isoforms and PGIS. Furthermore, it is a source and a target of PGI. PGI and COX may be important to gamete function, embryo transport, and embryo development...
  31. ncbi Differential effects of mutations in human endothelial nitric oxide synthase at residues Tyr-357 and Arg-365 on L-arginine hydroxylation and GN-hydroxy-L-arginine oxidation
    Pei Feng Chen
    Vascular Biology Research Center and Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Arch Biochem Biophys 411:83-92. 2003
    ..73 microM H(4)B to achieve EC(50). The differential effect of mutation on Arg and NHA oxidation suggests that distinct heme-based active oxidants are responsible for each step of NO synthesis...
  32. ncbi Structural elements contribute to the calcium/calmodulin dependence on enzyme activation in human endothelial nitric-oxide synthase
    Pei Feng Chen
    Vascular Biology Research Center and Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas 77225, USA
    J Biol Chem 278:52392-400. 2003
    ....
  33. ncbi Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study
    Christie M Ballantyne
    Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Tex 77030, USA
    Arch Intern Med 165:2479-84. 2005
    ..We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke...
  34. ncbi Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation
    Jun Yang Liou
    Vascular Biology Research Center, Brown Foundation Institute of Molecular Medicine, Houston, TX 77030 1503, USA
    Arterioscler Thromb Vasc Biol 26:1481-7. 2006
    ..To determine the role of prostacyclin (PGI2) in protecting endothelial cells (ECs) from apoptosis and elucidate the protective mechanism...
  35. pmc Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding
    Wu Guo Deng
    Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center at Houston, 77030, USA
    Blood 108:518-24. 2006
    ..These results suggest that melatonin inhibits COX-2 and iNOS transcriptional activation by inhibiting p300 HAT activity, thereby suppressing p52 acetylation, binding, and transactivation...
  36. ncbi Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay
    Wu Guo Deng
    University of Texas Houston Medical School, University of Texas Health Science Center, 6431 Fannin, MSB 5 016, Houston, TX 95616, USA
    Anal Biochem 323:12-8. 2003
    ....
  37. pmc Two synthetic peptides corresponding to the proximal heme-binding domain and CD1 domain of human endothelial nitric-oxide synthase inhibit the oxygenase activity by interacting with CaM
    Pei Feng Chen
    Vascular Biology Research Center, Department of Internal Medicine, The University of Texas Health Science Center at Houston, TX, USA
    Arch Biochem Biophys 486:132-40. 2009
    ..The results suggest that multiple regions of eNOS might interact with CaM with differential Ca(2+) sensitivity in vivo. A possible mechanism in regulating eNOS activation and deactivation is proposed...
  38. ncbi Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study
    Shun Kohsaka
    Texas Heart Institute, Baylor College of Medicine, Houston, TX, United States
    Atherosclerosis 196:926-30. 2008
    ..The present study explored whether the COX-2 G-765C polymorphism contributes to increased incidence of coronary heart disease (CHD) or stroke in the large prospective Atherosclerosis Risk in Communities (ARIC) Study...
  39. ncbi Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure
    Reynolds M Delgado
    Department of Adult Cardiology, Texas Heart Institute at St Luke s Episcopal Hospital, Houston, Tex 77030, USA
    Circulation 109:1428-33. 2004
    ..Because COX-2 inhibitors are useful in treating many inflammation-mediated diseases, we asked whether COX-2 inhibition can attenuate heart failure progression...
  40. ncbi The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease
    Vahid Afshar-Kharghan
    Thrombosis Research Section, Department of Medicine, BCM 286, N1319, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Blood 103:963-5. 2004
    ..In African Americans, the CC genotype (homozygous with 2 repeats) is associated with a lower risk of CHD events than all other genotypes...
  41. ncbi P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study
    Kelly A Volcik
    Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030, USA
    Atherosclerosis 186:74-9. 2006
    ....
  42. ncbi Analysis of protein-DNA binding by streptavidin-agarose pulldown
    Kenneth K Wu
    Division of Hematology, Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX, USA
    Methods Mol Biol 338:281-90. 2006
    ..This method has been shown to be useful in determining the regulation of binding of transactivators, p300/CBP, and associated proteins to the cyclooxygenase-2 (COX-2) promoter...
  43. ncbi Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding
    Wu Guo Deng
    University of Texas Health Science Center, Houston, TX 77030 1503, USA
    Arterioscler Thromb Vasc Biol 27:1752-9. 2007
    ..Cyclooxygenase-2 (COX-2) and interferon gamma (IFNgamma) are overexpressed in vascular inflammatory and atherosclerotic lesions. We postulated that IFNgamma suppresses COX-2 expression at the transcriptional level...
  44. pmc Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection
    Anthony W Ashton
    Department of Medicine, Divisions of Cardiology and Infectious Disease, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Exp Med 204:929-40. 2007
    ..cruzi infection is possibly an important determinant of mortality and parasitism. A deeper understanding of the role of TXA(2) may result in novel therapeutic targets for a disease with limited treatment options...
  45. ncbi Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction
    Heng Lin
    Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Circulation 105:1962-9. 2002
    ..We tested the hypothesis that bicistronic cyclooxygenase-1 (COX-1)/prostacyclin synthase (PGIS) and COX-1 gene transfer reduce cerebral infarct volume by augmenting synthesis of protective prostaglandins...
  46. ncbi Hyperhomocyst(e)inemia and hemostatic factors: the atherosclerosis risk in communities study
    Pamela J Schreiner
    Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, MN 55454 1015, USA
    Ann Epidemiol 12:228-36. 2002
    ..To determine whether homocyst(e)ine (H(e)) is related to hemostatic factors in a population-based sample without evidence of cardiovascular disease...
  47. doi Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway
    Jun Yang Liou
    National Health Research Institutes, 35 Keyan Rd, Zhunan Township, Miaoli County 350, Taiwan
    Mol Pharmacol 74:1399-406. 2008
    ..Our findings suggest that NSAIDs, but not aspirin (<1 mM) induce endothelial apoptosis via suppression of PPARdelta-mediated 14-3-3epsilon expression...
  48. ncbi C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study
    Aaron R Folsom
    Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minn 55454 1015, USA
    Am Heart J 144:233-8. 2002
    ..C-reactive protein, a plasma marker of inflammation, is a marker of CHD risk but has been studied in few prospective investigations of the general population...
  49. ncbi Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study
    Aaron R Folsom
    Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454 1015, USA
    Arterioscler Thromb Vasc Biol 22:1018-22. 2002
    ..Attributable risk estimates suggest that low protein C levels account for approximately 2.5% of venous thromboembolic events in the ARIC population...
  50. ncbi Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators
    Karsten Schroer
    Institut fur Pharmakologie und Klinische Pharmakologie, Heinrich Heine Universtät Düsseldorf, Dusseldorf, Germany
    Circulation 105:2760-5. 2002
    ..COX-2 promoter activity is induced by proinflammatory mediators, but the role of cyclic adenosine monophosphate response element (CRE) in promoter stimulation remains unclear...
  51. ncbi TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death
    I Shing Yu
    Graduate Institute of Medical Technology, Department of Pathology, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan
    Blood 104:135-42. 2004
    ..The TXAS-deleted mice will be valuable for investigating the roles of arachidonate metabolic shunt in various pathophysiologic processes...
  52. ncbi Molecular basis of estrogen-induced cyclooxygenase type 1 upregulation in endothelial cells
    Linda L Gibson
    Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, TX 75390, USA
    Circ Res 96:518-25. 2005
    ..In addition, the process may be initiated by cytoplasmic ERalpha, and critical receptor elements reside within the amino terminus...
  53. ncbi 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury
    Teng Nan Lin
    Neuroscience Division, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Arterioscler Thromb Vasc Biol 26:481-7. 2006
    ..The aim of this study is to assess the effect of 15d-PGJ2 on neuroprotection...
  54. ncbi An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study
    Aaron R Folsom
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454 1015, USA
    Arch Intern Med 166:1368-73. 2006
    ..There has been interest in recent years in whether additional, and in particular novel, risk factors or blood markers, such as C-reactive protein, can enhance existing coronary heart disease (CHD) prediction models...
  55. ncbi Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways
    Mo Liu
    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China
    FASEB J 21:1586-96. 2007
    ..PKC epsilon-specific siRNA also attenuated the phosphorylation of JNK. Our results provide evidence that helps us understand the function of SRAS-CoV spike protein in SARS pathogenesis...
  56. ncbi Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
    Nena Aleksic
    Vascular Biology Research Center and Hematology Division, University of Texas Houston Medical School 77030, USA
    Arterioscler Thromb Vasc Biol 22:348-52. 2002
    ..This prospective study did not provide evidence of a reduced CHD risk for the FXIIIA 34Leu allele...
  57. pmc Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans
    Kang Cheng
    Department of Cardiovascular Diseases, Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065, USA
    Proc Natl Acad Sci U S A 103:6682-7. 2006
    ..These studies suggest that DP1 receptor antagonism may be an effective means to suppress NA-induced flushing in humans...
  58. ncbi Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor
    Kenneth K Wu
    Department of Cardiovascular Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA
    Atherosclerosis 181:251-9. 2005
    ..This mouse model may provide insight into the mechanistic link between type 2 diabetes and atherosclerosis as well as serve as a valuable tool for evaluating therapeutics...
  59. ncbi Hypercoagulable states and strokes
    Nena Matijevic
    Curr Atheroscler Rep 8:324-9. 2006
    ..Furthermore, causal relationship has not been established...
  60. ncbi Diabetic atherosclerosis mouse models
    Kenneth K Wu
    Department of Cardiovascular Disease, Merck Research Laboratories, RY 80W 250, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    Atherosclerosis 191:241-9. 2007
    ....
  61. ncbi Heparin cofactor II levels do not predict the development of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study
    Tusar K Giri
    Arterioscler Thromb Vasc Biol 25:2689-90. 2005

Research Grants14

  1. EICOSANOIDS AND NO IN CEREBROVASCULAR THROMBOSIS
    Kenneth Wu; Fiscal Year: 2003
    ..It is intended that this program will enable several laboratories to work individually and together to achieve the highest degree of innovating and productivity. ..
  2. ARACHIDONATE METABOLISM IN BLOOD AND VASCULAR CELLS
    Kenneth Wu; Fiscal Year: 2002
    ..These investigations will provide novel and important information regarding the molecular mechanisms of TXA2 and PGI2 synthesis and will be valuable for studying their role s in vascular thrombosis and vascular diseases. ..
  3. ARACHIDONATE METABOLISM IN BLOOD AND VASCULAR CELLS
    Kenneth Wu; Fiscal Year: 1999
    ....
  4. Arachidonic Acid Metabolism in Blood and Vascular Cells
    Jun Yang Liou; Fiscal Year: 2006
    ..Information provided by studies from this renewal application will have great impact on understanding the fundamental cytoprotection process and offer an excellent opportunity for developing new therapeutic agents. ..